These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 28891187)

  • 1. Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in refractory Behçet disease uveitis and concomitant bladder papillary carcinoma.
    Orlando I; Vitale A; Rigante D; Lopalco G; Fabiani C; Cantarini L
    Intern Med J; 2017 Sep; 47(9):1086-1088. PubMed ID: 28891187
    [No Abstract]   [Full Text] [Related]  

  • 2. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
    Fabiani C; Vitale A; Emmi G; Lopalco G; Vannozzi L; Guerriero S; Gentileschi S; Bacherini D; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
    Clin Rheumatol; 2017 Jan; 36(1):191-197. PubMed ID: 27981463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease.
    Fabiani C; Vitale A; Rigante D; Emmi G; Lopalco G; Di Scala G; Sota J; Orlando I; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
    Ocul Immunol Inflamm; 2020; 28(2):298-304. PubMed ID: 30148652
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term efficacy and safety of anakinra in a patient with Behçet's disease and concomitant tuberculosis infection.
    Emmi G; Silvestri E; Squatrito D; Vitale A; Bacherini D; Vannozzi L; Emmi L; D'Elios MM; Cantarini L; Prisco D
    Int J Dermatol; 2017 Feb; 56(2):218-220. PubMed ID: 27336860
    [No Abstract]   [Full Text] [Related]  

  • 5. Anakinra for resistant Behçet uveitis: why not?
    Emmi G; Silvestri E; Cameli AM; Bacherini D; Vannozzi L; Squatrito D; Emmi L
    Clin Exp Rheumatol; 2013; 31(3 Suppl 77):152-3. PubMed ID: 24064028
    [No Abstract]   [Full Text] [Related]  

  • 6. Switch from anakinra to canakinumab in a severe case of CINCA syndrome.
    Rigante D; Verrecchia E; Falsini B; Manna R
    Int J Rheum Dis; 2016 Dec; 19(12):1354-1356. PubMed ID: 26585548
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of anakinra in refractory Behçet's disease sacroiliitis.
    Caso F; Rigante D; Vitale A; Lucherini OM; Cantarini L
    Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S171. PubMed ID: 24709061
    [No Abstract]   [Full Text] [Related]  

  • 8. IL-1 inhibition with anakinra in a patient with refractory gout.
    Singh D; Huston KK
    J Clin Rheumatol; 2009 Oct; 15(7):366. PubMed ID: 20009976
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effects and safety of infliximab administration in refractory uveoretinitis with Behçet's disease].
    Tanaka H; Sugita S; Yamada Y; Kawaguchi T; Iwanaga Y; Kamoi K; Yokota M; Takase H; Mochizuki M
    Nippon Ganka Gakkai Zasshi; 2010 Feb; 114(2):87-95. PubMed ID: 20187505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-1 blockade in neuro-Behçet's disease: a case-based reflection.
    Vitale A; Rigante D; Caso F; Franceschini R; Cantarini L
    Int J Rheum Dis; 2017 Aug; 20(8):1046-1049. PubMed ID: 26032112
    [No Abstract]   [Full Text] [Related]  

  • 11. Interleukin-1 Inhibition in Behçet's disease.
    Vitale A; Rigante D; Lopalco G; Selmi C; Galeazzi M; Iannone F; Cantarini L
    Isr Med Assoc J; 2016; 18(3-4):171-6. PubMed ID: 27228638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease.
    Cantarini L; Lopalco G; Caso F; Costa L; Iannone F; Lapadula G; Anelli MG; Franceschini R; Menicacci C; Galeazzi M; Selmi C; Rigante D
    Autoimmun Rev; 2015 Jan; 14(1):1-9. PubMed ID: 25151975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of infliximab on refractory uveitis in Behcet's disease.
    Sayarlioglu M; Cinal A; Topcu N; Demirok A
    Ann Pharmacother; 2004 May; 38(5):901-2. PubMed ID: 15010522
    [No Abstract]   [Full Text] [Related]  

  • 14. The efficacy of a single dose of infliximab in the treatment of Behçet's disease uveitis.
    Arayssi T; Hamra R; Homeidan F; Uthman I; Awwad ST; Mroue K; Mansour W; Bashshur ZF
    Clin Exp Rheumatol; 2005; 23(3):427. PubMed ID: 15971438
    [No Abstract]   [Full Text] [Related]  

  • 15. Blind insight: eyeing anti-tumor necrosis factor treatment in uveitis associated with Behçet's disease.
    Rosenbaum JT
    J Rheumatol; 2004 Jul; 31(7):1241-3. PubMed ID: 15229938
    [No Abstract]   [Full Text] [Related]  

  • 16. Timing of recurrent uveitis in patients with Behcet's disease receiving infliximab treatment.
    Yamada Y; Sugita S; Tanaka H; Kamoi K; Takase H; Mochizuki M
    Br J Ophthalmol; 2011 Feb; 95(2):205-8. PubMed ID: 20542984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab.
    Leccese P; Latanza L; D'Angelo S; Padula A; Olivieri I
    Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S93. PubMed ID: 21813069
    [No Abstract]   [Full Text] [Related]  

  • 19. Behçet disease-associated uveitis successfully treated with golimumab.
    Mesquida M; Victoria Hernández M; Llorenç V; Pelegrín L; Espinosa G; Dick AD; Adán A
    Ocul Immunol Inflamm; 2013 Apr; 21(2):160-2. PubMed ID: 23252659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study.
    Emmi G; Talarico R; Lopalco G; Cimaz R; Cantini F; Viapiana O; Olivieri I; Goldoni M; Vitale A; Silvestri E; Prisco D; Lapadula G; Galeazzi M; Iannone F; Cantarini L
    Clin Rheumatol; 2016 May; 35(5):1281-6. PubMed ID: 26156661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.